An observational study in Mesothelioma, Small Cell Lung Cancer, NSCLC, sponsored by Pierian Biosciences. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-16.
Sponsored by Pierian Biosciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Mesothelioma with a site in United States — 35 open to participants now, 51 under way, 1 of them phase 3. Mesothelioma · United States.
Among the 189 studies in Mesothelioma with a site in United States, this one is the 19th largest by enrollment of the 23 observational ones that give a count, is one of 6 that started in 2012, is one of 23 observational ones, and was the 49th registered.
305 studies on the registry are indexed under Mesothelioma; 59 are open to participants now.
Browse Mesothelioma studies →35 of the 189 studies in Mesothelioma with a site in United States are open now. Recruiting first, the newest first:
Oliver Jonas · Sites in United States
Ages 18+
SHY Therapeutics · Sites in United States
Ages 18+
Orion Corporation, Orion Pharma · Sites in United States, Denmark, Finland and 4 more countries
Ages 18+
IDEAYA Biosciences · Sites in United States, Korea, Republic of
Ages 18+
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 47 Mesothelioma studies recruiting now, 32 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 105 · Phase 2 73 · Phase 3 6
First in 2000; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 146 across 42 observational studies indexed under Mesothelioma.
Median enrollment 44 across the 165 interventional studies, 100 across the 23 observational. Of the 124 that completed or were terminated, 54 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 189 have an industry lead sponsor. The 10 most frequent:
Pierian Biosciences is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Pierian Biosciences has 1 study filed under Mesothelioma — fewer than ten, so there is no comparison to draw.
15 of the studies in Mesothelioma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT05238883HiFiBiO TherapeuticsA Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
| NCT05647265Alliance for Clinical Trials in OncologyTesting the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | 2026-12-15 |
| NCT04857372Novartis PharmaceuticalsA Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | 2027-01-07 |
| NCT05873686Nuvectis Pharma, Inc.A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 189 studies in Mesothelioma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Testing Mayo Clinic cancer patients with the results being correlated with prior patient therapy, performance status, and extent of disease.
This study will be conducted in two phases.
During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech MiCK assay laboratory to determine the ease of sample acquisition, processing, transport, and assay interpretation.
Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed that the sample acquisition, processing, transport, and assay interpretation are appropriate, we will proceed with the Demonstration Phase.
During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the results will be correlated with prior patient therapy, performance status, and extent of disease.
20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Complete response and survival
Time frame: 1 year
The record gives a start of Jun 2012, a primary completion of Jan 2015 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pierian Biosciences